临床试验/NCT05238311

NCT05238311No Longer Available不适用

Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)

Pfizer0 个研究点开始时间: 2022年2月14日最近更新: 2025年2月4日

适应症

相关药物

试验速览

阶段: 不适用
状态: No Longer Available
发起方: Pfizer

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

Provide pre-approval single-patient Expanded Access (Compassionate Use) of elranatamab for patients with relapsed/refractory multiple myeloma

详细描述

In Expanded Access, treating physicians are the Sponsors

Expanded Access requests from treating physicians should be directed to www.pfizercares.com Availability will depend on location.

研究设计

研究类型: Expanded Access

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

未提供

排除标准

未提供

研究者

发起方

申办方类型

Industry

责任方

Sponsor

相似试验

Provide Pre-approval Single Patient Expanded Access (Compassionate Use) of Etrasimod for Patients.Colitis, Ulcerative

NCT06025227Pfizer

Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)Metastatic Castration-Resistant Prostate Cancer

NCT05650476Pfizer

Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600)Alopecia Areata

NCT05522556Pfizer

Pre-approval Single-patient Expanded Access for Abrocitinib (PF-04965842)Severe Uncontrolled Atopic Dermatitis

NCT05466578Pfizer

No Longer Available

Provide Pre-approval Single-patient Expanded Access (Compassionate Use) of VYD222 for Patients With Symptomatic COVID-19 Refractory to Other TreatmentsCOVID-19

NCT06004128Invivyd, Inc.